|
Use of topical tacrolimus in ophthalmology: Nonsystematic review
Morgana Arima Vedovato1, Thaynara Queiroz Mendes Do Carmo1, Livia Cristina Rios2, Vinicius Cidral Corrêa1, Fernanda Ribeiro Oliveira1, Nelson Chamma Capelanes3, Bernardo Kaplan Moscovici4
1 Department of Ophthalmology, Paulista Ophthalmology Unit – UPO, São Paulo, Brazil
2 Department of Ophthalmology, Paulista Ophthalmology Unit – UPO, São Paulo; Department of Ophthalmology, Sorocaba Eye Banking, Banco de Olhos de Sorocaba – BOS, Sorocaba, Brazil
3 Department of Ophthalmology, Paulista Ophthalmology Unit – UPO; Department of Visual Sciences, Federal University of São Paulo, UNIFESP, São Paulo, Brazil
4 Department of Visual Sciences, Federal University of São Paulo, UNIFESP, São Paulo, Brazil
Correspondence Address:
Dr. Morgana Arima Vedovato
Avenida Redenção, 465, Ap 113, Bairro Jardim Do Mar, São Bernardo Do Campo - São Paulo
Brazil
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/PAJO.PAJO_45_20
|
|
The two immunosuppressants most used topically in ophthalmology are cyclosporine (CS) and tacrolimus (TL). Their mechanism of action is similar, but the TL is ten to a hundred times more powerful than the CS. We reviewed the studies found in the literature on the use of topical TL and described them, as follows, divided by indication of use. Topical TL is effective and safe against inflammatory and immunological processes of the ocular surface, although it is less powerful than corticosteroids, it has fewer side effects.
|
